A Phase 1/2 interventional study of TP04HN106 and Saline in Amyotrophic Lateral Sclerosis, sponsored by Talengen Institute of Life Sciences, Shenzhen, P.R. China.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Talengen Institute of Life Sciences, Shenzhen, P.R. China. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Amyotrophic Lateral Sclerosis with a site in China — 24 open to participants now, 29 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · China.
Among the 55 studies in Amyotrophic Lateral Sclerosis with a site in China, this one is the 12th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 13 of the 28 other live ones, and was the 42nd registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →24 of the 55 studies in Amyotrophic Lateral Sclerosis with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhimeng Biopharma, Inc. · Sites in China
Ages 18–65
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Sites in China
Ages 18–75
First People's Hospital of Hangzhou · Sites in China
Ages 18–80
Shanghai StairMed Technology Co., Ltd. · Sites in China
Ages 18–80
Hong Chen · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 15 · Phase 3 2 · Phase 4 3
First in 2006; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 24 across the 39 interventional studies, 226 across the 16 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 55 have an industry lead sponsor. The 10 most frequent:
Talengen Institute of Life Sciences, Shenzhen, P.R. China. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Talengen Institute of Life Sciences, Shenzhen, P.R. China. has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
12 of the studies in Amyotrophic Lateral Sclerosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07082192Phase 3Shanghai Zhimeng Biopharma, Inc.A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | 2027-09-30 |
| NCT06493279RJK Biopharma LtdEvaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis | 2026-11-30 |
| NCT06671236Novabio TherapeuticsClinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases | 2026-12 |
| NCT06765499First People's Hospital of HangzhouThe Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease | 2026-12-30 |
| NCT06726577Talengen Institute of Life Sciences, Shenzhen, P.R. China.TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 55 studies in Amyotrophic Lateral Sclerosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design.
This experiment is divided into two groups: the experimental drug group and the placebo group. Successful participants will be randomly assigned to the two groups, with an expected enrollment of 60 participants. There will be 30 participants in the experimental drug group and 30 participants in the placebo group. During the treatment period, the experimental drug group received intravenous injections of 0.5mL/kg TP04HN106 each time; The placebo group received intravenous injections of 0.5mL/kg of saline each time. During the extension period, all subjects received intravenous injection of 0.5mL/kg TP04HN106. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.
The subjects who were successfully screened in the experiment were enrolled in sequence, and the safety, tolerability, efficacy, and pharmacokinetic characteristics of the experimental drug were evaluated after administration. The entire trial includes a screening period of 1 week, a treatment period of 12 weeks (including 3 treatment cycles, each treatment cycle of 4 weeks), an extension period of 12 weeks (including 3 treatment cycles, each treatment cycle of 4 weeks), and a follow-up period of 4 weeks. In addition, some subjects underwent a 1-week single dose PK study before the start of the treatment period; In addition, during the first treatment cycle of the treatment period, some subjects were selected for multiple dosing PK studies.
We plan to conduct a single dose PK study among 12 subjects, with 6 subjects in the experimental group and 6 subjects in the control group; Multiple dose PK studies were conducted among 12 subjects, with 6 subjects in the experimental group and 6 sujects in the control group. It is not allowed for the same subject to participate in both single dose and multiple dose PK studies simultaneously.
The 1st to 12th subjects planned to be enrolled in the trial will undergo a single dose PK study. After the first dose, venous blood will be collected from the 12 subjects according to the blood sample collection requirements, and their PK characteristics will be evaluated. The observation period for single dose administration is one week. After completing the final blood sample collection and safety assessment, the subjects enter the treatment period, extension period, and follow-up period.
The 13th to 24th subjects planned to be enrolled in the trial will undergo multiple dose PK studies. These 12 subjects will have their venous blood collected according to the blood sample collection requirements during the first treatment cycle of the treatment period, and their PK characteristics will be evaluated. After completing the treatment period, the subjects will enter the extension period and follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Poor compliance or other researchers believe that there are any circumstances that are not suitable for inclusion.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TP04HN106
Drug: Saline
During the treatment period, the experimental drug group received intravenous injections of 0.5mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.5mL/kg TP04HN106.
The placebo group received intravenous injections of 0.83mL/kg of saline each time. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.
Amyotrophic Lateral Sclerosis Rating Scale (ALSFRS-R)
The Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) measures the severity of functional disorders. This scale measures three functional domains, namely medullary function, motor function, and respiratory function. The evaluation will consist of 12 questions, with scores ranging from 0 (non functional) to 4 (fully functional), for a total score of 48, which will indicate the highest level of functionality.
Time frame: Baseline, 10th week
ALSFRS-R
The Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) measures the severity of functional disorders. This scale measures three functional domains, namely medullary function, motor function, and respiratory function. The evaluation will consist of 12 questions, with scores ranging from 0 (non functional) to 4 (fully functional), for a total score of 48, which will indicate the highest level of functionality.
Time frame: Baseline, week 2, 6, 12, 14, 18, 22, and 28
Rasch Global Disability Assessment Scale (ROADS) scores
The Rasch Global Disability Assessment Scale (ROADS) scores is a comprehensive functional impairment assessment scale for amyotrophic lateral sclerosis syndrome. This scale consists of 28 items, arranged in order from the easiest action to the most difficult action, with a total score of 56 points
Time frame: Baseline, week 2, 6, 10, 12, 14, 18, 22, and 28
FVC%
The change value/rate of FVC% compared to baseline at weeks 2, 6, 10, 12, 14, 18, 22, and 28;
Time frame: Basline, weeks 2, 6, 10, 12, 14, 18, 22, and 28
Muscle strength
Changes in muscle strength from baseline as measured by a handheld dynamometer (HHD) at weeks 2, 6, 10, 12, 14, 18, 22, and 28;
Time frame: Baseline,week 2, 6, 10, 12, 14, 18, 22, and 28;weeks 2, 6, 10, 12, 14, 18, 22, and 28
Neurofilament light chain level
Change in the levels of Neurofilament light chain (NFL) in the subjects' venous plasma at week 10 and 22
Time frame: Baseline,week 10,week 22
CMAP amplitude
Changes in neuromuscular electrophysiological examination (CMAP amplitude measurement of clinically affected area) relative to baseline at week 10 and 22.
Time frame: Baseline,week 10,week 22
Incidence of permanent invasive breathing or oxygen assistance/death
Incidence of permanent invasive breathing or oxygen assistance/death during the trial;
Time frame: Through study completion, an average of 28 weeks
Started Jun 2026 (actual). Primary completion is estimated for Jan 2027, 7 months after the start.
Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 7 months is below that.
Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2026, on Oct 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Talengen Institute of Life Sciences, Shenzhen, P.R. China.